GCP
CPRX

GSA Capital Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

GSA Capital Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$624K Buy
25,214
+13,124
+109% +$313K 0.04% 778
2025
Q4 		$282K Buy
+12,090
New +$269K 0.02% 1203
2025
Q3 		– Sell
-27,656
Closed -$600K – 1714
2025
Q2 		$600K Buy
27,656
+5,072
+22% +$120K 0.04% 790
2025
Q1 		$548K Sell
22,584
-40,303
-64% -$908K 0.05% 741
2024
Q4 		$1.31M Buy
62,887
+31,450
+100% +$676K 0.1% 244
2024
Q3 		$625K Buy
+31,437
New +$583K 0.05% 771
2024
Q2 		– Sell
-59,838
Closed -$954K – 1680
2024
Q1 		$954K Buy
+59,838
New +$902K 0.08% 470
2022
Q3 		– Sell
-106,172
Closed -$744K – 1569
2022
Q2 		$744K Buy
106,172
+69,931
+193% +$513K 0.11% 272
2022
Q1 		$300K Buy
36,241
+12,313
+51% +$87K 0.04% 890
2021
Q4 		$162K Buy
+23,928
New +$157K 0.02% 1258
2021
Q3 		– Sell
-23,855
Closed -$137K – 1488
2021
Q2 		$137K Sell
23,855
-67,035
-74% -$346K 0.02% 1225
2021
Q1 		$419K Sell
90,890
-9,715
-10% -$38.6K 0.07% 445
2020
Q4 		$336K Buy
+100,605
New +$338K 0.06% 676
2020
Q2 		– Sell
-85,680
Closed -$330K – 693
2020
Q1 		$330K Sell
85,680
-101,816
-54% -$418K 0.08% 424
2019
Q4 		$703K Buy
187,496
+152,858
+441% +$715K 0.08% 422
2019
Q3 		$184K Buy
34,638
+8,418
+32% +$44.8K 0.02% 1189
2019
Q2 		$101K Buy
+26,220
New +$113K 0.01% 1344
2018
Q4 		– Sell
-202,845
Closed -$767K – 1398
2018
Q3 		$767K Sell
202,845
-177,760
-47% -$557K 0.04% 841
2018
Q2 		$1.19M Buy
380,605
+284,409
+296% +$863K 0.06% 637
2018
Q1 		$230K Buy
+96,196
New +$320K 0.01% 1422
2017
Q4 		– Sell
-479,196
Closed -$1.21M – 1590
2017
Q3 		$1.21M Buy
+479,196
New +$1.31M 0.08% 396
2016
Q4 		– Sell
-745,077
Closed -$812K – 1783
2016
Q3 		$812K Buy
745,077
+125,300
+20% +$113K 0.04% 737
2016
Q2 		$440K Buy
+619,777
New +$499K 0.02% 1151

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSA Capital Partners's CPRX Position: Q1 2026 in Review

GSA Capital Partners increased its Catalyst Pharmaceutical (CPRX) stake by 109% in Q1 2026, buying an estimated $313K and bringing the position to 25,214 shares worth $624K. The position accounts for 0.04% of the portfolio, ranked #778.

GSA Capital Partners first reported a position in CPRX in Q2 2016 and has held it in 23 quarters since. The position peaked at $1.31M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • GSA Capital Partners held 25,214 shares of Catalyst Pharmaceutical worth $624K as of Q1 2026.
  • GSA Capital Partners bought 13,124 Catalyst Pharmaceutical shares in Q1 2026, an estimated $313K.
  • Catalyst Pharmaceutical made up 0.04% of GSA Capital Partners's portfolio in Q1 2026, its #778 holding.
  • GSA Capital Partners first reported a position in Catalyst Pharmaceutical in Q2 2016 and has held it in 23 quarters since.
  • GSA Capital Partners's Catalyst Pharmaceutical position peaked at $1.31M in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.